We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Exploratory Study Using Nanotechnology to Detect Biomarkers of Parkinson's Disease From Exhaled Breath

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01246336
Recruitment Status : Completed
First Posted : November 23, 2010
Last Update Posted : October 31, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
Parkinson's disease is diagnosed clinically, because biomarkers that may help in diagnosis and differential diagnosis are not yet available. Exhaled breath testing may yield a "breath-print" that can be used to distinguish healthy and diseased states.

Condition or disease Intervention/treatment
Parkinson's Disease Parkinsonism Other: collection of exhaled breath

Study Design

Study Type : Observational
Actual Enrollment : 41 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Exploratory Study to Detect Volatile Biomarkers of Idiopathic Parkinson's Disease and Parkinsonism From Exhaled Breath Using a Nanomedical Artificial Olfactory System.
Study Start Date : August 2009
Primary Completion Date : January 2012
Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Group/Cohort Intervention/treatment
Patients with parkinsonism
Patients suffering from Parkinson's disease or parkinsonism
Other: collection of exhaled breath
no intervention
Healthy controls
Patients not suffering from Parkinson's disease or any other neurological disorder
Other: collection of exhaled breath
no intervention

Outcome Measures

Primary Outcome Measures :
  1. Nanosensory detection [ Time Frame: immediate ]
    analyze combinations of nanomaterial-based sensors (organically functionalized carbon nanotubes and gold nanoparticles)

Biospecimen Retention:   Samples Without DNA
Exhaled breath

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients diagnosed with Idiopathic Parkinson's disease and Parkinsonism will be included.

Inclusion Criteria:

  • Patients with Parkinsonism

Exclusion Criteria:

  • Severe dementia
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01246336

Sponsors and Collaborators
Rambam Health Care Campus
Technion, Israel Institute of Technology
Principal Investigator: Ilana Schlesinger, MD Rambam Health Care Campus
More Information

Responsible Party: Ilana Schlesinger, Ilana Schleainger, Rambam Health Care Campus, Rambam Health Care Campus
ClinicalTrials.gov Identifier: NCT01246336     History of Changes
Other Study ID Numbers: RMB09-0196
First Posted: November 23, 2010    Key Record Dates
Last Update Posted: October 31, 2017
Last Verified: October 2017

Keywords provided by Ilana Schlesinger, Rambam Health Care Campus:
Parkinson's disease, Parkinsonism
Exhaled breath

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases